Stage I Breast Carcinoma

Also known as: Early Breast cancer / Breast Cancer Stage I / Carcinoma Breast Stage I / Breast Cancer, Stage I / Stage I Breast Cancer / Breast carcinoma stage I / Breast carcinoma NOS stage I / Breast cancer NOS stage I

DrugDrug NameDrug Description
DB01217AnastrozoleAnastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens.
DB00990ExemestaneExemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation.
DB00014GoserelinGoserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
DB01006LetrozoleLetrozole (INN, trade name Femara®) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast cancer Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. Letrozole blocks production of estrogens in this way by competitive, reversible binding to the heme of its cytochrome P450 unit. The action is specific, and letrozole does not reduce production of mineralo- or corticosteroids. In contrast, the antiestrogenic action of tamoxifen, the major medical therapy prior to the arrival of aromatase inhibitors, is due to its interfering with the estrogen receptor, rather than inhibiting estrogen production. Letrozole is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women. Side effects include signs and symptoms of hypoestrogenism. There is concern that long term use may lead to osteoporosis, which is why prescriptions of Letrozole are often accompanied by prescriptions of osteoporosis-fighting medication such as Fosamax. Letrozole has shown to reduce estrogen levels by 98 percent while raising testosterone levels. The anti-estrogen action of letrozole is preferred by athletes and bodybuilders for use during a steroid cycle to reduce bloating due to excess water retention and prevent the formation of gynecomastia related breast tissue that is a side effect of some anabolic steroids. Usage above 2.5 mg/day is known to potentially temporarily kill sex drive. Above 5mg/day for extended periods may cause kidney problems. Letrozole has also been shown to delay the fusing of the growth plates in adolescents. This may boost the effectiveness of growth hormone, and thus Letrozole is used to treat adolescents and children with short stature.
DB06366PertuzumabPertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. FDA approved June 8, 2012.
DrugDrug NamePhaseStatusCount
DB00159Icosapent1Active Not Recruiting1
DB00331Metformin1Active Not Recruiting1
DB11133Omega-3 fatty acids1Active Not Recruiting1
DB12483Copanlisib1 / 2Recruiting1
DB01006Letrozole1 / 2Recruiting1
DB09073Palbociclib1 / 2Recruiting1
DB11126Calcium gluconate2Completed1
DB00531Cyclophosphamide2Active Not Recruiting1
DB00012Darbepoetin alfa2Completed1
DB00997Doxorubicin2Active Not Recruiting1
DB00641Simvastatin2Active Not Recruiting1
DB05773Trastuzumab emtansine2Active Not Recruiting1
DB00399Zoledronic acid2Completed1
DB00531Cyclophosphamide3Active Not Recruiting1
DB01248Docetaxel3Active Not Recruiting1
DB00997Doxorubicin3Active Not Recruiting1
DB01229Paclitaxel3Active Not Recruiting1
DB06366Pertuzumab3Active Not Recruiting1
DB11730Ribociclib3Not Yet Recruiting1
DB00072Trastuzumab3Active Not Recruiting1
DB01101CapecitabineNot AvailableCompleted1
DB00493CefotaximeNot AvailableCompleted1
DB00531CyclophosphamideNot AvailableCompleted2
DB01234DexamethasoneNot AvailableCompleted1
DB00514DextromethorphanNot AvailableCompleted1
DB00997DoxorubicinNot AvailableCompleted1
DB00445EpirubicinNot AvailableCompleted1
DB09374Indocyanine green acid formNot AvailableActive Not Recruiting1
DB00904OndansetronNot AvailableCompleted1
DB00377PalonosetronNot AvailableCompleted1
DB02546VorinostatNot AvailableCompleted1